Clinical Trials Browser

Recruiting × tislelizumab × CNS × Clear all

NCT06353360 2024-08-09

TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.

Phase 2 Recruiting

Glioblastoma

NCT05512351 2022-09-27

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma

Phase 2 Recruiting

Oligodendroglioma